The report provides a detailed analysis essential for establishing a Telavancin production plant. It encompasses all critical aspects necessary for Telavancin production, including the cost of Telavancin production, Telavancin plant cost, Telavancin production costs, and the overall Telavancin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Telavancin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Telavancin is a bactericidal lipoglycopeptide antibiotic, a semi-synthetic vancomycin derivative. It has dual action that includes stopping cell wall synthesis and disrupting bacterial membranes. It is used for treating complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive pathogens. It is also used in hospital-acquired and ventilator-associated bacterial pneumonia (when alternatives are unsuitable. It provides activity against MRSA, VISA, and hVISA strains with rapid bactericidal effects and good lung penetration. It works as an option for multidrug-resistant Gram-positive infections in adults under medical supervision. Its common side effects include nausea, vomiting, diarrhoea, foamy urine, metallic taste, headache, chills, dry skin, and red man syndrome (flushing and rash).
The market for Telavancin is influenced by growing antimicrobial resistance against Gram-positive pathogens in hospital-acquired pneumonia and skin infections. Its usage as a critical vancomycin alternative, fuelled by hospital formulary expansions, contributes to its market growth.
The regulatory approvals in developing markets like China, and the rising peptide antibiotics demand under stewardship programs that favour lipoglycopeptides for serious infections boosts its demand. Its dependency on Cumberland Pharmaceuticals risks shortages and high pricing pressures through hospital tenders affects industrial Telavancin procurement. Other factors like regulatory compliance challenges, including USDMF and sterile production standards, with strategies like starter packs and inventory buffers impacts its sourcing strategies.
Raw Material for Telavancin Production
According to the Telavancin production plant project report, the key raw materials used in the production of Telavancin include Decylamine, Glyoxal 1,1-Dimethylacetal, 9-Fluorenylmethyl chloroformate, Vancomycin Hydrochloride, and Aminomethylphosphonic Acid.
Production Process of Telavancin
The extensive Telavancin production cost report consists of the following major industrial production process:
- From Decylamine and Glyoxal 1,1-Dimethylacetal: The production of Telavancin starts with a reaction between decylamine and glyoxal 1,1-dimethylacetal. These chemicals go through reductive amination to form an imino intermediate. The imino group is protected using 9-fluorenylmethyl chloroformate (Fmoc-Cl), followed by hydrochloric acid hydrolysis of the acetal to yield N-Fmoc-decylaminoethanal. This intermediate reacts with Vancomycin hydrochloride by reductive amination. The Fmoc group is deprotected, and the resulting amine goes through a Mannich reaction with aminomethylphosphonic acid to produce Telavancin.
Telavancin has the molecular formula of C80H106Cl2N11O27P with a molecular weight of 1755.65 g/mol. It appears as a white to off-white lyophilised powder or crystalline solid. It contains a complex heptapeptide core with decylaminoethyl side chain, phosphono-methylamino group, and multiple sugar moieties conferring amphiphilicity. It has a density of around 1.6 g/cm³ and high protein binding (>90% to albumin). It shows low water solubility, which requires reconstitution in 5% dextrose or saline for IV use. It has a topological polar surface area of 598-607 Ų with 23 hydrogen bond donors, 29 acceptors, rotatable bonds 30-31, and 10 rings. Its volume of distribution is 0.14 L/kg, plasma clearance 12-13 mL/h/kg, and elimination half-life 6-9 hours by renal (8-9 mL/h/kg).
